Comparing Gepants for Acute Migraine Treatment

In this MEDtalk, Lanfranco Pellesi, MD, PhD, Clinical Pharmacology, University of Southern Denmark, reflects on clinical data for the three gepants ubrogepant, rimegepant, and zavegepant in acute migraine treatment. He shares insights into their efficacy based on NNT values, safety profiles, and how these treatments offer important alternatives for patients with contraindications or poor response to triptans.